Skip to main content

What the FDA labels say about taking them together

Ensitrelvir and lomitapide

Ensitrelvir's FDA label of June 3, 2026 names lomitapide in its drug interactions section; the lomitapide label PlainMeds reads does not name ensitrelvir. The ensitrelvir label: “Co-administration is contraindicated due to potential for hepatotoxicity and gastrointestinal adverse reactions.”

Check it at the source: the ensitrelvir FDA label on DailyMed (effective June 3, 2026, Shionogi Inc.); the lomitapide FDA label on DailyMed (effective March 30, 2026, Chiesi USA, Inc.).

What does the ensitrelvir label say about lomitapide?

Ensitrelvir label, drug interactions

Drug Class: Microsomal triglyceride transfer protein (MTTP) inhibitors; Drug (s) within Class: lomitapide; Effect on Drug Concentration: ↑ lomitapide; Clinical Comment: Co-administration is contraindicated due to potential for hepatotoxicity and gastrointestinal adverse reactions.

Source: FDA drug label (XOCOVA), Shionogi Inc., effective June 3, 2026 (SPL set 526acf60-abc3-2cc2-e063-6294a90affa6), via openFDA; the full label on DailyMed

What does the lomitapide label say about ensitrelvir?

Lomitapide's label (effective March 30, 2026) does not name ensitrelvir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Juxtapid), Chiesi USA, Inc., effective March 30, 2026 (SPL set 61a0be9d-ee58-43e0-b5cb-141011835081), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Ensitrelvir generic labelers
0Lomitapide generic labelers
EnsitrelvirLomitapide
Labeled forCOVID-19High cholesterol
Boxed warningNoYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?